.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 7,083,808

« Back to Dashboard

Claims for Patent: 7,083,808

Title:Controlled/modified release oral methylphenidate formulations
Abstract: The invention is directed to oral modified/controlled release methylphenidate formulations which provide a rapid initial onset of effect and a prolonged duration of effect. Preferably, the peak concentration is lower than that provided by the reference standard for immediate release methylphenidate formulations, and the duration of effect falls rapidly at the end of the dosing interval so as not to affect the appetite of the patient at dinner nor the patient's sleep thereafter.
Inventor(s): Goldenheim; Paul D. (Wilton, CT), Sackler; Richard S. (Greenwich, CT), Krishnamurthy; Thinnayam N. (Ontario, CA), Darke; Andrew (Ontario, CA), Oshlaci; Benjamin (New York, NY)
Assignee: Euro-Celtique S.A. (Luxembourg, LU)
Application Number:10/741,081
Patent Claims: 1. An oral dosage form comprising an effective amount of methylphenidate or a pharmaceutically acceptable salt thereof, wherein a portion of the methylphenidate or pharmaceutically acceptable salt thereof is in immediate release form and a portion of the methylphenidate or pharmaceutically acceptable salt thereof is in controlled release form, the controlled release form comprising a substrate comprising about 60% to about 70% of the methylphenidate or a pharmaceutically acceptable salt thereof and at least one pH dependent release modifying coating, wherein the pH dependent release modifying coating is applied to obtain a weight gain from about 2 to about 25% of the substrate, the formulation providing a time to maximum plasma concentration at about 0.5 to about 4 hours after oral administration, a peak plasma concentration from about 3 ng/ml to about 6.5 ng/ml per 20 mg dose of methylphenidate contained in the oral dosage form, wherein the peak concentration is from about 1.0 to about 2.0 times the plasma concentration of methylphenidate provided by the formulation at about 9 hours after oral administration, wherein the formulation provides an in-vitro dissolution as follows: TABLE-US-00043 Time % Methylphenidate (hours) HCl dissolved 0.25 0 45% 1 5 50% 4 40 90% 8 NLT 60% 12 NLT 80%

and wherein the duration of effect provided by the methylphenidate contained in the formulation falls below effective plasma concentrations at about 8 to about 12 hours after oral administration, wherein about 30% to about 40% of the methylphenidate or pharmaceutically acceptable salt thereof is in immediate release form.

2. The oral dosage form of claim 1, wherein the oral dosage form provides a time to maximum plasma concentration at about 0.5 to about 2 hours after oral administration.

3. The oral dosage form of claim 2, wherein the peak plasma concentration is from about 1.0 to about 1.7 times the plasma concentration of methylphenidate provided by the formulation at about 9 hours after oral administration.

4. The oral dosage form of claim 3, wherein the duration of effect provided by the methylphenidate contained in the oral dosage form falls below effective plasma concentrations at about 8 to about 10 hours after oral administration.

5. The oral dosage form of claim 1, which provides a "square wave" plasma profile as depicted by Formulation 1.

6. The oral dosage form of claim 1, which provides an in-vitro dissolution as follows: TABLE-US-00044 Time % Methylphenidate (hours) HCl dissolved 0.25 0 45% 1 10 50% 4 30 80% 8 NLT 65% 12 NLT 80%

7. The oral dosage form of claim 1, wherein the pH dependent release modifying coating is selected from the group consisting of shellac, cellulose acetate phthalate, polyvinyl acetate phthalate, hydroxypropylmethylcellulose phthalate, a pH dependent methacrylic acid ester copolymer and zein.

8. The oral dosage form of claim 7, wherein the pH dependent coating is a pH dependent methacrylic acid ester copolymer.

9. The oral dosage form of claim 1, wherein the substrate comprises methylphenidate or pharmaceutically acceptable salt thereof coated onto inert beads.

10. The oral dosage form of claim 9, wherein the coated inert beads are overcoated with at least a portion of the pH dependent release modifying coating.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc